Orphan Drug Exclusivity: In Narrow Application Of Catalyst Ruling, FDA Retains Its Existing Regs
Executive Summary
US FDA will continue to tie orphan exclusivity to uses or indications for which the drug was approved. Attorneys say this buys agency time to sort out complex policy and legal questions and continue to seek legislative fix. Additional litigation is also possible, as happened in Depomed case.
You may also be interested in...
Orphan Exclusivity Dilemma: Without Legislative Fix, US FDA May Seek New Regulation
FDA didn’t get policy rider it wanted which would have reversed the Catalyst court ruling that the agency cannot limit a drug’s orphan exclusivity to its approved indication. One attorney says the clearest path forward is for FDA to issue new rulemaking and face additional litigation.
US FDA Loses Orphan Exclusivity Case While HHS Wins Dismissal Of Pfizer Kickback Complaint
In rare loss for FDA, appeals court reverses district court decision tossing Catalyst’s suit over Orphan Drug Act, saying deference should not have been granted to agency’s interpretation. District court finds it is too early to rule on one Pfizer charity co-pay program but backs broad reading of Anti-Kickback Statute.
Eagle Will Be Last Firm To Bypass FDA's Orphan Drug Exclusivity Requirement
Court orders US FDA to award Bendeka seven years of exclusivity without requiring clinical superiority test; law codifying FDA policy passed prior to suit and is not retroactive.